332 related articles for article (PubMed ID: 19519447)
1. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 trans-signaling in inflammatory bowel disease.
Mitsuyama K; Sata M; Rose-John S
Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
7. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
8. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease.
Hosokawa T; Kusugami K; Ina K; Ando T; Shinoda M; Imada A; Ohsuga M; Sakai T; Matsuura T; Ito K; Kaneshiro K
J Gastroenterol Hepatol; 1999 Oct; 14(10):987-96. PubMed ID: 10530495
[TBL] [Abstract][Full Text] [Related]
11. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer.
Atreya R; Neurath MF
Clin Rev Allergy Immunol; 2005 Jun; 28(3):187-96. PubMed ID: 16129903
[TBL] [Abstract][Full Text] [Related]
12. Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling.
Gesiorowski A; Ettich J; Werner J; Wittich C; Pieper S; Padrini G; Behnke K; Floss DM; Lang PA; Moll JM; Scheller J
J Biol Chem; 2023 Nov; 299(11):105343. PubMed ID: 37838173
[TBL] [Abstract][Full Text] [Related]
13. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
15. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
16. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer.
Atreya R; Neurath MF
Curr Drug Targets; 2008 May; 9(5):369-74. PubMed ID: 18473764
[TBL] [Abstract][Full Text] [Related]
17. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.
Scheller J; Garbers C; Rose-John S
Semin Immunol; 2014 Feb; 26(1):2-12. PubMed ID: 24325804
[TBL] [Abstract][Full Text] [Related]
20. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
Rose-John S; Schooltink H
Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]